Pharsight — Investor Presentation (May 2005)
38 slides from Pharsight's investor presentation, May 13, 2005

Slide 1: Pharsight Investor Presentation May 2005
Exhibit 99.1 Exhibit Pharsight Investor May Shawn Cynthia 2005 O’Connor 99.1 Stephens Presentation Corporation President SVP & CFO & CEO

Slide 2: Forward-Looking Statements
Forward-Looking This customer expansion software, remains These development, large Quarterly date Copyright 2 Pharsight hereof, presentation pharmaceutical forward-looking atdemand, including Report of © the and 2005 scope changes sole Pharsight on contains Statements Pharsight. potential discretion

Slide 3: Delivering client improvement in the clinical drug development process
Deliveringis… Accelerating Improving Copyright 3 Pharsight © client breakthrough 2005 client development Pharsight. product improvement time-to-market All efficiencies rights in reserved. the clinical drug development process to pharmaceutical companies by…

Slide 4: Pharsight Background, Profile and Recent Progress
Background Profile Business Recent – Copyright 4 Pharsight WinNonlin® Founded Headquarters East Headcount US, OTCBB: Market Pharsight® Opportunity Drug Unique 25Demonstrable consecutive Europe, Coast Financial Model and leading provider ©1995; PHST Office 2005 -Products Knowledgebase Australia to ap

Slide 5: Executive Team
Executive Shawn President Cynthia The James Mark Hovde Mona SVP Daniel IVAX, William GloboMax, Austin-College Greg Nancy Russ VP Rene Managing Copyright Pharsight &Walt Research Global Consulting & Global Marketing Drug Wada, Lee, Bruno, Hovde Lead Sowiski Hayden Risch Associates, Merrell Weiner, O’

Slide 6: Our Market Opportunity: Drug Development Productivity Decline
Our Drug High Combinatorial Significant Increase Clinical $48 Productivity To process compounds, preclinical enter •drug produce or 1 2 3 Copyright 6 Pharsight Avg Genomics Rational Long, Of Only isexceed 2002 PhRMA Bain Decline approved Billion1 Market 5,000 $802M2 clinical throughput Development c

Slide 7: Our Market Opportunity: Total Estimated Development Expenditure
Our Market Total $70,000 $50,000 $60,000 Estimated $30,000 2003 $0 Branded Development Copyright 7 Pharsight –Pharma 2004 2008 Phase $20,000 Pharma at ©2005 Opportunity: 34% CAGR 2005 11.0% Expenditure I –2006 8.6% Generics $10,000 of III Pharsight. Total 2007 $80,000 Spend Biotech Estimates by 2008

Slide 8: Our Market Opportunity: Shifting Failure Rates and Decreasing Costs
Our Decreasing Impact – 1 Copyright 8 Pharsight Today Chance 25 Shifting Improving Pacific Market Years of=Research of Shifting 5% 8% © Ago FDA Opportunity: drug ability 2005 of approval =Approval failures successfully 14% Pharsight. Failure Institute to predict approval rate1 from Increasing Rates

Slide 9: Software Products
Software Products Pharsight

Slide 10: Software Products Overview: Key Offerings
Overview Desktop Pharsight® Drug – Copyright 10 Pharsight WinNonlin® Trial WinNonMix® Industry Computer Population (“PD”) Enterprise Software-Based Model Simulator™ Software Modeling of © Standard Knowledge Assisted Data Explorer™ Key 2005 Pharmacokinetic (“WNL™”) (“WNM™”) Software Management Commun

Slide 11: WinNonlin Key Offerings
WinNonlin® Industry Key Potential Sales – ASP Copyright 11 Pharsight WNL Used Increases Extensive One-button Maintain Provide Subscription Low-cost Distributor Software Benefits =Model $5,000 to 5.0 Standard Growth simulate upgrade ©market productivity release inside built-in 2005 in (“WNL™”) export

Slide 12: Trial Simulator Key Offerings
Trial State-of-the-Art Key Growth Sales – ASP Copyright 12 Pharsight Minimize Intuitive, Formalize Quantify Built-in Reduce Increase Subscription Low-cost Distributor Software Benefits =Simulator™ Model $16,000 Drivers cost facility © potential uncertainty protocol-based inside risk assumptions 2005

Slide 13: WinNonMix Key Offerings
WinNonMix® Nonlinear Key Growth Sales – ASP Copyright 13 Pharsight Extensive NONMEM Built-in Estimation Maximum Increase Provide Subscription Low-cost Distributor Software Benefits =Model $7,000 Drivers upgrade report-ready Mixed © interoperability inside built-in likelihood 2005 algorithms in data

Slide 14: Pharsight Knowledge Server Key Offerings
Pharsight® Enterprise Key Potential Sales – ASP Copyright 14 Pharsight Tendency Dramatically Increases Reduces Supports Installed Optimize Provide PKS Subscription Software Direct Software Benefits =Model 3.0 $10,000 sales Growth upgrade © release Data long base compliance license productivity adopt

Slide 15: Drug Model Explorer Key Offerings
Drug Software-Based Recently Key Potential Sales – Copyright 15 Pharsight Web-server Desktop Facilitates Enables Expand Increase Bundling Subscription Software Benefits Model Released Growth client utility more © interoperability application with more Explorer™ 2005 application Offerings and flexibl

Slide 16: Software Market Acceptance Over Top 50 Pharma
Software Over All Our 9 – 1 2 Copyright 16 Pharsight As ofTop 13 440 Pharma software the active of 1,000 active March Top 50Products Exec © Pharma2 PKSTM customers 20 50 seats 2005 applications 31, 50: Pharma2 2005 Pharsight. Market Pharmaceutical customers license as are ofare Acceptance1 March at

Slide 17: Strategic Consulting Services
Strategic Consulting Services Pharsight

Slide 18: Strategic Consulting Services
Strategicquantitative, Formal, Increases Decreases Reduces Improves Copyright 18 Pharsightfinancial Consulting drug clinical late time-to-market © 2005 stage development quality investment Pharsight. attrition Services model-based andproductivity All commercial Methodology rights decision-making res

Slide 19: Strategic Consulting Services Offerings Across Development Stages
Preclinical (I/IIa) Candidate first-trial Scaling LEVEL OF Dose Support Strategic Copyright 19 Pharsight justification (IIb/III) (competitors, Product in-licensing design Consulting consulting Proof-of-concept ©Early 2005 in-man/ profile Phase and Pharsight. services and Services analogues) optimiza

Slide 20: Strategic Consulting Services Customer Testimonial
Strategic Aventis Based Evista.” Frank success.” Executive FORBES Copyright 20 Pharsight Douglas onturned Douglas Consulting that ASAP VP © 2005 simulation, ofto Aventis |Drug estimates aOctober Pharsight. computer Services Innovation Chief “We 7,that 2002 All model Scientific Customer stopped the r

Slide 21: Strategic Consulting Services Potential Growth Drivers
Strategic Industry Internal – Copyright 21 Pharsight Increased FDA Expanding Expanded Continuing Critical Factors Factors Consulting ©acceptance service 2005 scope recruitment PathPharsight. and offering Initiative Services of increasing of modeling best All Potential & rights efficiency brightest a

Slide 22: Strategic Consulting Current Market Penetration
Strategic 40% Top 30% Current Market 1 2 Copyright 22 Pharsight As Pharma 10 50 of Market Pharma2 Opportunity March Clients Consulting Exec © Penetration 2005 31, 50:2005 Pharsight. Pharmaceutical ServicesAll Market rights Executive, Penetration reserved. May– Current 2004 Clients1

Slide 23: Strategic Consulting Projects Over Fiscal Year
Strategic – Over Typical 1 2 Copyright 23 Pharsight As 13 of Pharma 25the 119 March workplans active Consulting projects Exec © Top 2005 31, clients 50: 50 engaged 2005 Pharsight. Pharma range Pharmaceutical Services during from are during All fiscal Market several active rights Fiscal Executive, ye

Slide 24: Financial Overview
Financial Overview Pharsight

Slide 25: FY05 Results and FY06 Objectives
FY05 Fiscal Continued Y-Y 2nd Net Profitability Achieved Additional DMX Trial Copyright 25 Pharsight income consecutive revenue Simulator Accomplishments Web Yearpositive © revenue new Server 2005 of in growth 2005 $2.7 both upgrade product year Results annual Pharsight. growth million, business of

Slide 26: Summary Statement of Operations
Summary (‘000s Q4 FY05 Revenues Income Net EPS WASO Copyright 26 Pharsight Q4 income (common), FY04 except -(loss) basic $6,025 Statement ©(loss) FY05 2005 per from 19,226 basic $5,403 share 807 attributable Pharsight. FY04 operations of$19,055 308 Operations data) 0.03 $22,593 2,733 $All 19,122 to

Slide 27: Summary Operating Results: Software Products
Summary Q4 FY05 OPERATING Initial Revenues 22% Gross Income PRODUCT Desktop 1,530 Copyright 27 Pharsight Q42,288 16% FY04 profit license (loss) products Operating ©Total 19% LINE 2,195 FY05 2005 $from RESULTS 450 1,530 $$REVENUES 79% Pharsight. FY04 2,769 operations 1,357 16% Results 16% 2,465 100%

Slide 28: Summary Operating Results: Strategic Consulting Services
Summary STRATEGIC (‘000s) Gross Revenues Income Q4 FY05 $ Copyright 28 Pharsight 3,256 Q4FY04 profit (loss) 100% Operating ©FY05 2005 CONSULTING from $ 1,972 Pharsight. FY04 operations Results 100% –$10,515 All SERVICES Strategic rights100% reserved. Consulting $8,054 100% Q4 & FY2005 1,675 51% 780

Slide 29: Quarterly Revenues
Quarterly Software (‘000s) $7,000 Q1 $0 Copyright 29 Pharsight FY04$6,000 Products Q2 Revenues © 2005 FY04 $5,000 Pharsight. Strategic Q3$4,000 FY04Consulting All $3,000 Q4 rights FY04 $2,000 reserved. Q1 FY05 $1,000 Q2 FY05 Q3 FY05 Q4 FY05

Slide 30: Quarterly Gross Profit by Segment
Quarterly (Percentage Strategic 90% 70% Q1 0% Copyright 30 Pharsight FY04 60%Consulting Q2 Gross 50% ©of2005 FY04 Segment 40% Profit Pharsight. Q3 30% 80%FY04 Revenues) 20% Software All Q4 10%rights FY04 Products reserved. Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05

Slide 31: Sequential Profitability
Sequential Profitability (‘000s) Revenues $5,000 $5,500 $6,000 Q1 $3,500 $4,000 Copyright 31 Pharsight FY04 Q2$4,500 © Profitability achieved 2005 FY04Costs Pharsight. Q3Q4 FY04 &FY04 Expenses All Q4$6,500 rights FY04 reserved. Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05

Slide 32: Quarterly Operating Income
Quarterly $1,500 (000s) -$ Q1 Copyright 32 Pharsight 500 1,000 1,500 2,000 FY04 $1,000 Q2 Operating © 2005 FY04 $500Pharsight. Q3 $0 Income FY04Growth All Q4 rights FY04 reserved. Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05

Slide 33: Quarterly Operating Cash Flow
Quarterly $2,000 (‘000s) --$500 Q1 Copyright 33 Pharsight $1,500 FY04 $1,000 $1,500 Q2 Operating © 2005 FY04 $1,000 Pharsight. Q3 Cash $500 FY04 Flow $0All Q4 rights FY04 reserved. Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05

Slide 34: Summary Balance Sheet
Summary March Cash ASSETS LIABILITIES A/P Deferred Redeemable Copyright 34 Pharsight &&Accrued 31, Cash Revenue Balance © March Conv 2005 Equivalents &Expenses STOCKHOLDERS’ 31, -Pharsight. Sheet Pref Long (‘000s) Stock March $Term 3,497 10,579 All 2005 6,266 126 31, rights $2004 $2,518 2005 6,164 5

Slide 35: Equity Structure
Equity (All Preferred Common PIPE – Copyright 35 Pharsight Automatically At Warrants Series 1.8 Preferred Dividend Conversion: Upon Redemption: share election million Financing Structure close AShares Equivalent data © 1.8 exercisable conversion rights: 2005 of Units of million as at 6/02 public upo

Slide 36: Current Summary
Current Summary Increasing Continuing All Financially Copyright 36 Pharsight Support Pharma © Mindshare Stable Pharsight Our 2005 Market Drive & Pharsight. Healthy Investment for Towards Trends Quantitative-Based All Business Look Expansion rights in Sales, Favorable… Model… reserved. Marketing of M

Slide 37: Proprietary Notices
Proprietary Notices No Model All Copyright 37 Pharsight part contents other ExplorerTM, ofbrand Corporation. © this Notice Copyright 2005 document andPharsight. product DMXTM, WinNonlin®, ©2005 maynames All be Pharsight Trial rights reproduced are SimulatorTM WinNonMix® trademarks reserved. Corporat

Slide 38: Pharsight
Pharsight
Source: SEC EDGAR · 8-K filed May 13, 2005
More decks from Pharsight Corp
Q4 2007 Earnings Presentation45 slides · May 14, 2007
Investor Presentation (January 2007)41 slides · Jan 26, 2007
Q2 2007 Earnings Presentation33 slides · Nov 30, 2006
Q1 FY2007 Earnings Presentation37 slides · Aug 3, 2006
Investor Presentation (June 2006)36 slides · Jun 6, 2006
Investor Presentation (February 2006)31 slides · Feb 2, 2006